CCRA® — Certified Clinical Research Associate — Questions and Answers

Question 1: A 'certified copy' of a source document is acceptable when:

It is signed only by the CRA
It is created by the CRA during the monitoring visit
It is a verified copy that has been confirmed as an exact copy of the original through a documented process (Correct answer)
The original document has been destroyed

Correct answer: It is a verified copy that has been confirmed as an exact copy of the original through a documented process

A certified copy is a copy verified to be a true and accurate copy of the original through a documented certification process, and it may be retained in place of the original when needed.

Question 2: Under ICH E6(R2), what is the minimum content required in a monitoring visit report?

List of all subjects enrolled and their randomization codes
Enrollment numbers only
Protocol version and IRB approval number
Date of visit, site visited, CRA name, findings, deviations, and follow-up actions (Correct answer)

Correct answer: Date of visit, site visited, CRA name, findings, deviations, and follow-up actions

ICH E6(R2) requires monitoring reports to capture the visit date, site, monitor identity, findings, deviations, and any required follow-up actions.

Question 3: ICH E6(R2) defines 'essential documents' as those that individually and collectively permit evaluation of the conduct of a trial and:

The quality of the data produced (Correct answer)
The publication timeline
The financial costs incurred
The site selection criteria

Correct answer: The quality of the data produced

Essential documents allow evaluation of both the conduct of the trial and the quality of data generated, and are required to be maintained throughout and after the trial.

Question 4: Which of the following best describes 'open-label' trial design with respect to investigational product management?

IP is provided with no label or identification
Both subjects and investigators know which treatment is being administered, with no blinding of treatment assignment (Correct answer)
The IP label includes the subject's name publicly
Only the subject is unblinded while the investigator remains blinded

Correct answer: Both subjects and investigators know which treatment is being administered, with no blinding of treatment assignment

In an open-label trial, there is no blinding — both the subject and the site staff know which treatment the subject is receiving, simplifying IP management but introducing potential bias.

Question 5: Which GCP principle states that the rights, safety, and well-being of trial subjects are the most important considerations?

Data integrity principle
Ethical principle of primacy of subject protection (Correct answer)
Principle of equipoise
Scientific validity principle

Correct answer: Ethical principle of primacy of subject protection

ICH E6(R2) principle 2.3 explicitly states that the rights, safety, and well-being of trial subjects must prevail over the interests of science and society.

Question 6: What is the purpose of the Investigator's Brochure (IB)?

To record investigator qualifications and training history
To document subject-reported outcomes during the trial
To serve as the official FDA approval document for the drug
To provide the clinical and non-clinical data on the investigational product relevant to its study in humans (Correct answer)

Correct answer: To provide the clinical and non-clinical data on the investigational product relevant to its study in humans

The IB compiles all relevant preclinical and clinical data about the investigational product to guide safe and appropriate conduct of the trial.

Question 7: A 'temperature excursion' for investigational product occurs when:

The IP dispensing log shows missing entries
The IP expiration date passes without disposal
IP storage conditions deviate outside the protocol-specified temperature range (Correct answer)
The IP is shipped to an unapproved country

Correct answer: IP storage conditions deviate outside the protocol-specified temperature range

A temperature excursion is when IP is exposed to temperatures outside the specified storage range; the sponsor's medical/quality team must evaluate whether the affected IP remains usable.

Question 8: Statistical evaluation of subject data according to the group they were placed in despite not adhering to the study protocol

Intention to treat analysis (Correct answer)
A-b-a or withdrawal design
Random assignment
Blinding of subjects

Correct answer: Intention to treat analysis

Intention-to-treat (ITT) analysis is a statistical approach in clinical trials where all participants are analyzed in the groups to which they were originally randomized, regardless of whether they completed the intervention or adhered to the protocol. This method preserves the benefits of randomization and provides a more realistic estimate of the treatment effect in real-world settings, minimizing bias.

Question 9: During source data verification (SDV), the CRA finds that a lab value in the CRF was changed without documentation. What does this indicate?

A potential data integrity issue that must be queried and documented (Correct answer)
A minor clerical error that can be verbally corrected
Acceptable site practice to maintain clean data
Evidence of fraud that requires immediate trial suspension

Correct answer: A potential data integrity issue that must be queried and documented

Undocumented CRF changes violate ALCOA+ data integrity principles and must be investigated, queried, and documented in the monitoring report.

Question 10: A site investigator wants to add a new co-investigator to the trial team mid-study. What GCP-required steps must be completed before the new co-investigator can perform any study activities?

IRB approval, CV submission, GCP training documentation, and addition to the delegation log (Correct answer)
Only signature of a new CTA amendment is needed
Verbal approval from the CRA is sufficient
The sponsor must issue a formal protocol amendment

Correct answer: IRB approval, CV submission, GCP training documentation, and addition to the delegation log

New study personnel must have updated CVs on file, documented GCP training, IRB acknowledgment per site SOP, and be formally delegated responsibilities on the delegation of authority log.

Question 11: Which ICH E6(R2) principle requires that each individual involved in conducting a trial should be qualified by education, training, and experience?

Principle 12 — data integrity
Principle 3 — qualified personnel (Correct answer)
Principle 2 — IRB oversight
Principle 7 — confidentiality protection

Correct answer: Principle 3 — qualified personnel

ICH E6(R2) Principle 3 specifies that all trial personnel must be qualified by education, training, and experience to perform their tasks.

Question 12: Which regulation requires informed consent to be obtained in a language understandable to the subject?

45 CFR Part 46
21 CFR Part 56
21 CFR Part 50 (Correct answer)
ICH E6(R2) Section 4.8

Correct answer: 21 CFR Part 50

21 CFR Part 50 specifies that the information given to subjects must be in language understandable to the subject or their legally authorized representative.

Question 13: What is the purpose of a 'double-blind dummy' (matching placebo or active control) in a clinical trial?

To provide a backup supply of investigational product
To maintain blinding by ensuring all treatment arms have identical appearance, so neither subjects nor site staff can distinguish active from placebo (Correct answer)
To satisfy FDA labeling requirements
To reduce manufacturing costs

Correct answer: To maintain blinding by ensuring all treatment arms have identical appearance, so neither subjects nor site staff can distinguish active from placebo

Matching placebos or dummy controls are formulated to be identical in appearance, taste, and texture to the active product, preserving blinding integrity throughout the trial.

Question 14: What is the purpose of a pre-study site selection visit feasibility questionnaire sent to potential sites?

To obtain regulatory approvals from the FDA
To finalize the statistical analysis plan with site investigators
To gather initial information about site capabilities, patient population, and staff resources to determine suitability (Correct answer)
To collect subject consent before the trial begins

Correct answer: To gather initial information about site capabilities, patient population, and staff resources to determine suitability

Feasibility questionnaires help sponsors efficiently screen multiple sites to identify those most likely to meet enrollment targets and protocol requirements before investing in an on-site visit.

Question 15: A subject reports a new, unexpected, drug-related serious adverse event. According to ICH E6, within what timeframe must the investigator report this to the sponsor?

Within 15 calendar days
Within 48 hours of becoming aware
Within 24 hours of becoming aware (Correct answer)
Within 7 calendar days

Correct answer: Within 24 hours of becoming aware

ICH E6(R2) requires investigators to report all serious adverse events to the sponsor immediately, and no later than 24 hours of their becoming aware of the event.

Question 16: When EDC is used as the source of truth and data are entered directly into the EDC system without prior paper records, these data are called:

Transferred data
Secondary data
Derived data
eSource data (Correct answer)

Correct answer: eSource data

eSource refers to clinical trial data captured directly in electronic systems (e.g., EDC, EHR) as the original source, without an intermediate paper record being created.

Question 17: During a routine monitoring visit, the CRA discovers that the site has been enrolling subjects who do not meet the inclusion criteria. What is the FIRST action the CRA should take?

Document the finding and discuss it with the investigator during the visit (Correct answer)
Withdraw the non-compliant subjects from the study
Notify the IRB directly without informing the sponsor
Immediately suspend the trial at the site

Correct answer: Document the finding and discuss it with the investigator during the visit

The CRA should document the protocol deviation and discuss it with the investigator to understand the root cause before escalating per the monitoring plan.

Question 18: What is the purpose of a Pre-Study Visit (PSV) or Site Qualification Visit (SQV)?

To conduct final data lock activities
To re-consent subjects following a protocol amendment
To assess the site's suitability, resources, and investigator qualifications before trial startup (Correct answer)
To perform a closeout audit

Correct answer: To assess the site's suitability, resources, and investigator qualifications before trial startup

The PSV/SQV evaluates whether the site has the required patient population, qualified personnel, facilities, and investigator commitment to conduct the trial successfully.

Question 19: What is the minimum required retention period for clinical trial essential documents under FDA regulations?

10 years after study completion
2 years after a marketing application is approved, or 2 years after the IND is terminated if no application is filed (Correct answer)
2 years after the last subject's last visit
5 years after database lock

Correct answer: 2 years after a marketing application is approved, or 2 years after the IND is terminated if no application is filed

Under 21 CFR 312.62, investigational records must be retained for 2 years following the date a marketing application is approved, or 2 years after IND discontinuation if no application is submitted.

Question 20: A subject who previously signed informed consent now lacks decision-making capacity due to an adverse event. Who may provide continued consent for their participation?

The principal investigator may waive further consent
The site coordinator may re-consent on the subject's behalf
A legally authorized representative (LAR) as defined by applicable law (Correct answer)
The IRB must re-consent the subject at the next meeting

Correct answer: A legally authorized representative (LAR) as defined by applicable law

When a subject loses capacity, a legally authorized representative defined by applicable law and IRB-approved procedures may provide surrogate consent.

Question 21: Subject medication compliance (adherence) is most commonly assessed in clinical trials by:

Sponsor review of financial payment records
Subject self-report at final visit only
Pill/device counts, subject diaries, or plasma drug level measurements (Correct answer)
Investigator opinion during clinic visits

Correct answer: Pill/device counts, subject diaries, or plasma drug level measurements

Compliance is typically measured through returned pill counts, patient diary records of doses taken, and/or pharmacokinetic sampling to confirm drug exposure, as specified in the protocol.

Question 22: A 'data reconciliation' process between the safety database and the clinical database is performed to:

Reconcile laboratory values with imaging data
Match financial invoices with subject visit data
Ensure all adverse events captured in the safety system are accurately reflected in the clinical database and vice versa (Correct answer)
Confirm randomization assignments match enrollment logs

Correct answer: Ensure all adverse events captured in the safety system are accurately reflected in the clinical database and vice versa

Safety-to-clinical database reconciliation ensures that all adverse events, medications, and safety data are consistently recorded in both the safety reporting system and the clinical EDC.

Question 23: A 'comparator product' in a clinical trial refers to:

A backup supply of investigational product
A generic version of the investigational product
An approved product (or placebo) used as a reference against which the investigational product is evaluated (Correct answer)
A placebo without active ingredients

Correct answer: An approved product (or placebo) used as a reference against which the investigational product is evaluated

The comparator is an approved medicinal product or placebo used in a controlled trial to compare against the investigational product's safety and efficacy profile.

Question 24: A 'Competent Authority' in the context of EU clinical trial regulations refers to:

The IRB or Ethics Committee
The sponsor's medical monitor
The CRO project manager
A national regulatory body such as the MHRA or BfArM (Correct answer)

Correct answer: A national regulatory body such as the MHRA or BfArM

A Competent Authority is the national regulatory agency responsible for authorizing clinical trials in a given EU member state, such as the MHRA in the UK or BfArM in Germany.

Question 25: During a Site Initiation Visit (SIV), which of the following is the CRA's MOST critical responsibility?

Requesting a list of all patients who may be eligible for the study
Reviewing all previously published literature on the investigational product
Submitting the final Clinical Study Report to the IRB
Ensuring all site staff are trained and documented on the protocol before enrollment begins (Correct answer)

Correct answer: Ensuring all site staff are trained and documented on the protocol before enrollment begins

The SIV ensures all site personnel are adequately trained and that training documentation is complete before the first subject is enrolled.

Question 26: What is the definition of 'source data' according to ICH E6(R2)?

Data that has been verified and approved by the sponsor's data management team
Data entered directly into the electronic CRF by the site coordinator
Original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial (Correct answer)
Randomization codes held by the unblinded statistician

Correct answer: Original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial

Source data includes all original records (e.g., hospital records, lab printouts, diaries) and certified copies that document clinical trial activities.

Question 27: In a clinical trial using an Electronic Data Capture (EDC) system, audit trails serve to:

Eliminate the need for source document verification
Record all data entries, changes, deletions, and the identity of the person making changes with timestamps (Correct answer)
Automatically correct data entry errors
Replace the paper CRF process entirely

Correct answer: Record all data entries, changes, deletions, and the identity of the person making changes with timestamps

EDC audit trails create an automatic, computer-generated, time-stamped record of all actions taken in the system, supporting data integrity and regulatory inspection readiness.

Question 28: A Phase I clinical trial primarily evaluates:

Long-term safety over several years in post-marketing surveillance
Comparative effectiveness of two approved drugs
Safety, tolerability, pharmacokinetics, and maximum tolerated dose in a small group of subjects (Correct answer)
Efficacy compared to placebo in a large patient population

Correct answer: Safety, tolerability, pharmacokinetics, and maximum tolerated dose in a small group of subjects

Phase I trials focus on safety, tolerability, PK/PD properties, and dose escalation, typically in 20–100 healthy volunteers or patients.

Question 29: Which Belmont Report principle requires that the benefits of research be maximized and harms minimized?

Beneficence (Correct answer)
Justice
Respect for persons
Autonomy

Correct answer: Beneficence

The principle of beneficence obligates researchers to maximize possible benefits and minimize possible harms when conducting research with human subjects.

Question 30: What documentation must you submit in order to participate in a clinical research study?

Protocol
Case Report Form
Informed Consent Form (Correct answer)
Investigator's Brochure

Correct answer: Informed Consent Form

To participate in any clinical research study, every potential subject must submit an Informed Consent Form (ICF). This crucial document ensures that individuals are fully informed about the study's purpose, procedures, potential risks, and benefits before voluntarily agreeing to participate. Signing the ICF is a fundamental ethical and regulatory requirement designed to protect the rights and welfare of human subjects.

CCRA® — Certified Clinical Research Associate

The CCRA® credential, offered by ACRP, validates the knowledge and skills of clinical research associates who monitor clinical trials to ensure GCP compliance, participant safety, data integrity, and regulatory adherence across all phases of drug and device development.

125

Questions

180 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds